Antiproliferative properties of newly synthesized 19-nortestosterone analogs without substantial androgenic activity

András Gyovai, Renáta Minorics, Anita Kiss, E. Mernyák, G. Schneider, A. Szekeres, Erika Kerekes, I. Ocsovszki, I. Zupkó

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

19-Nortestosterone C-17 epimers with prominent antiproliferative properties have been previously described. In our present study, five novel 17a-19-nortestosterones (3-7) were synthesized to increase their beneficial biological activities with no associated undesired hormonal effects. The compounds were screened by a viability assay against a panel of human adherent gynecological cancer cell lines. Three of the tested derivatives (3-5) exhibited a remarkable inhibitory effect on the proliferation of HeLa cells with IC50 values lower than that of our reference agent cisplatin (CIS). These three active agents also displayed considerable cancer selectivity as evidenced by their weaker growth inhibitory effect on non-cancerous fibroblast cells compared to CIS. The most potent newly synthesized 17a-chloro derivative (3) was selected for additional experiments in order to characterize its mechanism of action. Since nandrolone (19-nortestosterone, 1) is a structural analog with selective antiproliferative action on cervical carcinoma cells, it was utilized as a positive control in these studies. A lactate dehydrogenase (LDH) assay demonstrated a moderate cytotoxic effect of the test compounds. Cell cycle disturbance and the elevation of the hypodiploid population elicited by the test agents were detected by flow cytometry following propidium staining. The proapoptotic effects of the tested steroids were confirmed by fluorescent microscopy and a caspase-3 activity assay. Treatment-related caspase-9 activation without a substantial change in caspase-8 activity indicates the induction of the intrinsic apoptotic pathway. The selected agents directly influence the rate of tubulin assembly as evidenced by a polymerization assay. Yeast-based reporter gene assay revealed that the androgenic activity of the novel 19-nortestosterone derivative 3 is by multiple orders of magnitude weaker than that of the reference agent 1. Based on the behavior of the examined compounds it can be concluded that a halogen substitution of the 19-nortestosterone scaffold at the 17a position may produce compounds with unique biological activities. The results of the present study support that structurally modified steroids with negligible hormonal activity are a promising basis for the research and development of novel anticancer agents.

Original languageEnglish
Article number825
JournalFrontiers in Pharmacology
Volume9
Issue numberJUL
DOIs
Publication statusPublished - Jul 27 2018

Fingerprint

Nandrolone
Cisplatin
Steroids
Halogens
Caspase 9
Caspase 8
Propidium
Tubulin
Reporter Genes
HeLa Cells
L-Lactate Dehydrogenase
Caspase 3
Polymerization
Antineoplastic Agents
Inhibitory Concentration 50
Microscopy
Neoplasms
Cell Cycle
Flow Cytometry
Fibroblasts

Keywords

  • 19-nortestosterone analogs
  • Androgenic activity
  • Antiproliferative action
  • Caspase
  • Cell cycle
  • HeLa Cells
  • Tubulin polymerization

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Antiproliferative properties of newly synthesized 19-nortestosterone analogs without substantial androgenic activity. / Gyovai, András; Minorics, Renáta; Kiss, Anita; Mernyák, E.; Schneider, G.; Szekeres, A.; Kerekes, Erika; Ocsovszki, I.; Zupkó, I.

In: Frontiers in Pharmacology, Vol. 9, No. JUL, 825, 27.07.2018.

Research output: Contribution to journalArticle

@article{428aa7eb3ea74be08bc9f15327f96496,
title = "Antiproliferative properties of newly synthesized 19-nortestosterone analogs without substantial androgenic activity",
abstract = "19-Nortestosterone C-17 epimers with prominent antiproliferative properties have been previously described. In our present study, five novel 17a-19-nortestosterones (3-7) were synthesized to increase their beneficial biological activities with no associated undesired hormonal effects. The compounds were screened by a viability assay against a panel of human adherent gynecological cancer cell lines. Three of the tested derivatives (3-5) exhibited a remarkable inhibitory effect on the proliferation of HeLa cells with IC50 values lower than that of our reference agent cisplatin (CIS). These three active agents also displayed considerable cancer selectivity as evidenced by their weaker growth inhibitory effect on non-cancerous fibroblast cells compared to CIS. The most potent newly synthesized 17a-chloro derivative (3) was selected for additional experiments in order to characterize its mechanism of action. Since nandrolone (19-nortestosterone, 1) is a structural analog with selective antiproliferative action on cervical carcinoma cells, it was utilized as a positive control in these studies. A lactate dehydrogenase (LDH) assay demonstrated a moderate cytotoxic effect of the test compounds. Cell cycle disturbance and the elevation of the hypodiploid population elicited by the test agents were detected by flow cytometry following propidium staining. The proapoptotic effects of the tested steroids were confirmed by fluorescent microscopy and a caspase-3 activity assay. Treatment-related caspase-9 activation without a substantial change in caspase-8 activity indicates the induction of the intrinsic apoptotic pathway. The selected agents directly influence the rate of tubulin assembly as evidenced by a polymerization assay. Yeast-based reporter gene assay revealed that the androgenic activity of the novel 19-nortestosterone derivative 3 is by multiple orders of magnitude weaker than that of the reference agent 1. Based on the behavior of the examined compounds it can be concluded that a halogen substitution of the 19-nortestosterone scaffold at the 17a position may produce compounds with unique biological activities. The results of the present study support that structurally modified steroids with negligible hormonal activity are a promising basis for the research and development of novel anticancer agents.",
keywords = "19-nortestosterone analogs, Androgenic activity, Antiproliferative action, Caspase, Cell cycle, HeLa Cells, Tubulin polymerization",
author = "Andr{\'a}s Gyovai and Ren{\'a}ta Minorics and Anita Kiss and E. Merny{\'a}k and G. Schneider and A. Szekeres and Erika Kerekes and I. Ocsovszki and I. Zupk{\'o}",
year = "2018",
month = "7",
day = "27",
doi = "10.3389/fphar.2018.00825",
language = "English",
volume = "9",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "JUL",

}

TY - JOUR

T1 - Antiproliferative properties of newly synthesized 19-nortestosterone analogs without substantial androgenic activity

AU - Gyovai, András

AU - Minorics, Renáta

AU - Kiss, Anita

AU - Mernyák, E.

AU - Schneider, G.

AU - Szekeres, A.

AU - Kerekes, Erika

AU - Ocsovszki, I.

AU - Zupkó, I.

PY - 2018/7/27

Y1 - 2018/7/27

N2 - 19-Nortestosterone C-17 epimers with prominent antiproliferative properties have been previously described. In our present study, five novel 17a-19-nortestosterones (3-7) were synthesized to increase their beneficial biological activities with no associated undesired hormonal effects. The compounds were screened by a viability assay against a panel of human adherent gynecological cancer cell lines. Three of the tested derivatives (3-5) exhibited a remarkable inhibitory effect on the proliferation of HeLa cells with IC50 values lower than that of our reference agent cisplatin (CIS). These three active agents also displayed considerable cancer selectivity as evidenced by their weaker growth inhibitory effect on non-cancerous fibroblast cells compared to CIS. The most potent newly synthesized 17a-chloro derivative (3) was selected for additional experiments in order to characterize its mechanism of action. Since nandrolone (19-nortestosterone, 1) is a structural analog with selective antiproliferative action on cervical carcinoma cells, it was utilized as a positive control in these studies. A lactate dehydrogenase (LDH) assay demonstrated a moderate cytotoxic effect of the test compounds. Cell cycle disturbance and the elevation of the hypodiploid population elicited by the test agents were detected by flow cytometry following propidium staining. The proapoptotic effects of the tested steroids were confirmed by fluorescent microscopy and a caspase-3 activity assay. Treatment-related caspase-9 activation without a substantial change in caspase-8 activity indicates the induction of the intrinsic apoptotic pathway. The selected agents directly influence the rate of tubulin assembly as evidenced by a polymerization assay. Yeast-based reporter gene assay revealed that the androgenic activity of the novel 19-nortestosterone derivative 3 is by multiple orders of magnitude weaker than that of the reference agent 1. Based on the behavior of the examined compounds it can be concluded that a halogen substitution of the 19-nortestosterone scaffold at the 17a position may produce compounds with unique biological activities. The results of the present study support that structurally modified steroids with negligible hormonal activity are a promising basis for the research and development of novel anticancer agents.

AB - 19-Nortestosterone C-17 epimers with prominent antiproliferative properties have been previously described. In our present study, five novel 17a-19-nortestosterones (3-7) were synthesized to increase their beneficial biological activities with no associated undesired hormonal effects. The compounds were screened by a viability assay against a panel of human adherent gynecological cancer cell lines. Three of the tested derivatives (3-5) exhibited a remarkable inhibitory effect on the proliferation of HeLa cells with IC50 values lower than that of our reference agent cisplatin (CIS). These three active agents also displayed considerable cancer selectivity as evidenced by their weaker growth inhibitory effect on non-cancerous fibroblast cells compared to CIS. The most potent newly synthesized 17a-chloro derivative (3) was selected for additional experiments in order to characterize its mechanism of action. Since nandrolone (19-nortestosterone, 1) is a structural analog with selective antiproliferative action on cervical carcinoma cells, it was utilized as a positive control in these studies. A lactate dehydrogenase (LDH) assay demonstrated a moderate cytotoxic effect of the test compounds. Cell cycle disturbance and the elevation of the hypodiploid population elicited by the test agents were detected by flow cytometry following propidium staining. The proapoptotic effects of the tested steroids were confirmed by fluorescent microscopy and a caspase-3 activity assay. Treatment-related caspase-9 activation without a substantial change in caspase-8 activity indicates the induction of the intrinsic apoptotic pathway. The selected agents directly influence the rate of tubulin assembly as evidenced by a polymerization assay. Yeast-based reporter gene assay revealed that the androgenic activity of the novel 19-nortestosterone derivative 3 is by multiple orders of magnitude weaker than that of the reference agent 1. Based on the behavior of the examined compounds it can be concluded that a halogen substitution of the 19-nortestosterone scaffold at the 17a position may produce compounds with unique biological activities. The results of the present study support that structurally modified steroids with negligible hormonal activity are a promising basis for the research and development of novel anticancer agents.

KW - 19-nortestosterone analogs

KW - Androgenic activity

KW - Antiproliferative action

KW - Caspase

KW - Cell cycle

KW - HeLa Cells

KW - Tubulin polymerization

UR - http://www.scopus.com/inward/record.url?scp=85050631997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050631997&partnerID=8YFLogxK

U2 - 10.3389/fphar.2018.00825

DO - 10.3389/fphar.2018.00825

M3 - Article

VL - 9

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - JUL

M1 - 825

ER -